Disease Diagnosis TRIZ Cases

A validated metabolic biomarker panel discriminates between stable and failing heart conditions in pediatric single ventricle subjects.

Antigen probe arrays analyze antibody reactivity patterns to differentiate specific autoimmune diseases.

Immobilized lectins capture specific glycans in fluid samples, enabling accurate diagnosis of mild and moderate traumatic brain injury.

Detecting HMGCR autoantibodies via immunoassay resolves diagnostic precision gaps, preventing inappropriate immunosuppression in statin-treated patients.

Germanium internal reflection element detects vibrational spectra from immobilized antibodies.

PAD1 autoantigens detect RA-specific autoantibodies, resolving low precision of traditional biomarkers.

Graph data structure determines PIRCHES to identify permissible mismatches, replacing laborious CTLpf assays with reliable computational analysis.

Segmenting diagnostics with a 0.01 to 1 ng/mL procalcitonin threshold resolves overlapping symptoms between cardiac insufficiency and pneumonia.

Neopterin level measurement predicts functional autonomy return in acute event patients.

Monoclonal antibody Das-1 detects immunoreactivity in pancreatic tissue samples to differentiate high-grade lesions from lower-grade neoplasms.

Isolating monocyte-macrophage cells to assess spontaneous osteoclast differentiation for early bone loss detection.

Measuring glycation at specific haptoglobin and albumin sites improves diagnostic specificity for type II diabetes without increasing measurement complexity.

Blood-based biomarker panel detects bipolar disorder using specific protein markers, resolving diagnostic ambiguity from symptom overlap.

Xanthene compounds generate fluorescent signals to measure ABC transporter activity, resolving low detection sensitivity of classical methods.

An ex vivo method detects intracellular disease marker fragments in living Monocyte Phagocyte System cells to assess catalytic activity.

Biotinylated capture molecules bind streptavidin on membranes, solving poor retention of small peptides in lateral flow assays.

Multi-marker antibody detection on a lateral flow assay strip eliminates false negatives in premature rupture of membranes diagnosis.

Tail fiber protein-coated nanoparticles shift absorption spectra via plasmonic coupling to identify bacterial serogroups without laborious conventional assays.

Metabolite biomarkers identify hereditary angioedema patients and predict acute attacks, resolving inadequate early detection in current diagnostic methods.

Multiplatform analysis combines immune phenotyping, serum polypeptides, and metabolites to diagnose autism spectrum disorders.

Fluorescent peptide probes bind amyloid beta oligomers to enable precise flow cytometry detection in biological samples.

Tandem mass spectrometry identifies and quantifies carboxyethylated valine modified hemoglobin in biological fluids.

Multi-stage nutrigenomic diagnostic system detects IgA and IgM antibodies in saliva and serum samples, resolving imprecise allergen identification.

Replacing limited physical exams with molecular HPV detection and multivariate risk analysis improves early diagnosis accuracy.

Detecting anti-Argonaute autoantibodies identifies autoimmune neurological diseases using a comprehensive biomarker panel.

Tryptophan levels detect mood disorder status and quantify improvements through objective biochemical measurements.

Quantifying intracellular metabolite efflux rates in permeabilized cancer cells using glutamine and pyruvate substrates.

Serum myomesin 3 levels detect pathological muscle degradation, replacing unreliable creatine kinase tests and painful biopsies with stable biomarkers.

Homogeneous assay method detects anti-CCP antibodies via nanoparticle turbidimetry, eliminating washing steps to increase throughput.

A modified RT-QuIC assay employs beads and a fluorophore to detect alpha-synuclein aggregates in biological samples.

A learning statistical classifier system analyzes biomarker concentrations to classify samples as irritable bowel syndrome or non-IBS.

SLIM-1 protein concentration measurement overcomes limited predictive value of existing markers to enable earlier heart failure diagnosis.

Capillary isoelectric focusing profiles protein post-translational modifications to classify non-alcoholic fatty liver disease without invasive biopsies.

Parallel reaction monitoring quantifies signature peptides for herpesvirus proteins, overcoming antibody limitations to enable precise temporal class detection.

Combining multiple biomarkers enables accurate Alzheimer's disease risk prediction.

Combining fractional C-reactive protein with troponin I resolves the trade-off between early ischemic signal availability and cardiac diagnostic specificity.

A multi-biomarker panel detects prostate cancer risk through solid-state binding interactions.

Segmenting multiple protein concentrations via mass spectrometry resolves early detection accuracy versus progression prediction reliability.

Ganglioside GM2 Activator Protein quantification in urine enables early acute renal failure detection before extensive tissue damage occurs.

Anti-CLEVER-1 antibody bexmarilimab treats non-inflamed tumors by converting immunosuppressive macrophages into pro-inflammatory phenotypes.

Measuring soluble TREM-1 concentrations resolves inadequate diagnostic reliability by providing precise severity assessment and complication prediction.

Replace urinary albumin measurements with podocalyxin detection to identify early-stage diabetic nephropathy before significant kidney damage occurs.

Proton nuclear magnetic resonance detects urine metabolites to stratify individuals prone to high fat diet-induced weight gain.

Phospho-specific antibodies detect BAD protein phosphorylation status to predict ovarian cancer cell responsiveness to platinum chemotherapy.

Protein expression profiling identifies idiopathic pneumonia syndrome risk via biomarkers, enabling targeted treatment without invasive lung biopsies.

Urine lateral flow assay detects the beta subunit of luteinizing hormone using specific binding members on a conjugate pad and membrane.

Carbamoyl phosphate synthetase 1 immunoassay detects early liver damage before clinical symptoms appear, resolving diagnosis delay.